Skip to main content

Advertisement

Table 1 Cell cycle analysis: Alternating treatment with sorafenib and lenvatinib SoLAT showed significant increase in the sub-G0/G1 population and induction of cell death in advanced PTC (GSP2 and GSP3)

From: SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

Status Sub-G0G1 G0G1 S G2/M
GSP2
Control 1.4 ± 0.05 49.5 ± 0.05 27.2 ± 0.09 21.9 ± 0.05
Sorafenib only 4.7 ± 0.08 51.3 ± 0.07 25.4 ± 0.09 18.6 ± 0.05
Lenvatinib only 9.8 ± 0.04 49.6 ± 0.03 27.4 ± 0.12 13.2 ± 0.04
SoLAT S + L 29.8 ± 0.09 46.7 ± 0.15 18.9 ± 0.05 4.6 ± 0.03
Sorafenib 7.5 ± 0.02 49.5 ± 0.07 30.6 ± 0.01 12.4 ± 0.08
Lenvatinib 21.9 ± 0.04 50.1 ± 0.12 22.3 ± 0.05 5.7 ± 0.02
Sorafenib 1.7 ± 0.07 49.3 ± 0.04 28.5 ± 0.05 20.5 ± 0.09
Lenvatinib 13.7 ± 0.15 48.3 ± 0.02 27.5 ± 0.01 10.5 ± 0.02
GSP3
Control 1.1 ± 0.03 49.8 ± 0.08 27.5 ± 0.15 21.6 ± 0.12
Sorafenib only 2.4 ± 0.04 51.6 ± 0.06 26.4 ± 0.05 19.6 ± 0.01
Lenvatinib only 13.6 ± 0.04 53.2 ± 0.03 24.5 ± 0.07 8.7 ± 0.05
SoLAT S + L 36.2 ± 0.15 45.6 ± 0.14 14.3 ± 0.19 3.9 ± 0.22
Sorafenib 2.7 ± 0.15 51.2 ± 0.12 26.7 ± 0.12 19.4 ± 17
Lenvatinib 32.4 ± 0.11 49.5 ± 0.21 13.5 ± 0.07 4.6 ± 0.15
Sorafenib 2.4 ± 0.15 52.8 ± 0.25 27.6 ± 0.14 17.2 ± 0.13
Lenvatinib 22.9 ± 0.24 55.1 ± 0.13 15.5 ± 0.19 6.5 ± 0.15